CEL-SCI Corporation to Present at the 8th Annual LD Micro Invitational
May 22 2018 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy biopharmaceutical company, today announced
that it will be presenting at the 8th annual LD Micro Invitational
on Tuesday, June 5 at 12:00 PM ET. Geert Kersten, Chief Executive
Officer of CEL-SCI, will be giving the presentation and meeting
with investors.
Mr. Kersten’s presentation will be webcast and available in the
Investor Relations section of the Company's website at
www.cel-sci.com/investor_relations.html. The webcast will be
archived for 90 days following the presentation.
The conference will be held at the Luxe Sunset Bel Air Hotel in
Los Angeles, California, will feature 230 companies in the
small-cap / micro-cap space, and will be attended by over 1,000
individuals.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. The firm hosts several
influential conferences annually (Invitational, Summit, and Main
Event).
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3
study is fully enrolled with 928 patients. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient’s immune system while it is still intact in order to have
the greatest possible impact on survival. Therefore, CEL-SCI treats
patients who are newly diagnosed with head and neck cancer with its
lead investigational immunotherapy Multikine (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma. CEL-SCI has
received patents for Multikine from the US, Europe, China and
Japan.
The Company’s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180522005303/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024